David Bernard Miklos MD PhD

Hematologic Oncology

Associate Professor of Medicine & Associate Chief - Blood & Marrow Transplantation, Clinical Director - Cancer Cell Therapy Program, Stanford University Medical Center

Join to View Full Profile

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
Yale School of MedicineClass of 1995

Certifications & Licensure

CA State Medical License 2004 - 2026
MA State Medical License 2001 - 2006
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Bone Marrow Grafting for Leukemia and Lymphoma
ENROLLING_BY_INVITATION
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD Start of enrollment: 2005 Jun 01
Completed
Phase 2
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease Start of enrollment: 2006 Aug 01
Completed
Not Applicable
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease Start of enrollment: 2008 Sep 01
Completed
Phase 1
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease Start of enrollment: 2010 Aug 01
Completed
Phase 1
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
COMPLETED
PHASE1, PHASE2
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Start of enrollment: 2017 Sep 01
ACTIVE_NOT_RECRUITING
PHASE1
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL Start of enrollment: 2020 Mar 24
Completed
Phase 1, Phase 2
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells Start of enrollment: 2022 Feb 14
Enrolling by invitation
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) Start of enrollment: 2022 Jan 24
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
Yi-Jiun Su, Anne Marijn Kramer, Mark P Hamilton, Neha Agarwal, Hrishikesh K Srinagesh
Cancer Discovery. 2025-04-02
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
Courtney J Smith, Anmol Goyal, Brian R Smith, Dasom Lee, Alexandria Jensen
Ejhaem. 2025-04-01
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.
David B Miklos, Peter A Riedell, Alex Bokun, Julio C Chavez, Stephen J Schuster
Targeted Oncology. 2025-03-01

Abstracts/Posters

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post_Axi-Cel
David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma
David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy
David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
David B. Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Immune Reconstitution and Long-Term Outcomes Following Allo-HCT with TLI-ATG and Post-Transplant Rituximab
David B Miklos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Advancing Care for Patients With GvHD: Making Sense of Recent Approvals and Late-Stage Compounds
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

CAR T-cell Therapy Moves into the Fast LaneDecember 20th, 2024
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaOctober 17th, 2024
Blood Test Predicts Chances of Lymphoma Relapse After TherapyAugust 6th, 2021
Join now to see all

Grant Support

Biology And Treatment Of Cutaneous SclerosisNational Cancer Institute2011
Allogeneic B Cell ResponsesNational Cancer Institute2007–2011
Biology And Treatment Of Cutaneous SclerosisNational Institute Of Allergy And Infectious Diseases2009–2010
Microarray Analysis Of H-Y Antibodies In Human TransplantationNational Heart, Lung, And Blood Institute2007–2008
Identification Of Minor Histocompatibility AntigensNational Heart, Lung, And Blood Institute2005–2006
Identification Of Minor Histocompatibility AntigensNational Heart, Lung, And Blood Institute2002–2004